Fig. 7From: A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemiaPrediction of drugs for the high-risk and low-risk score groups. A, B Sensitivity analysis of anti-cancer drugs in the high and low FSMscore groups performed using the Wilcoxon test; A: The Cancer Genome Atlas cohort and B: The Gene Expression Omnibus cohort. In the red dashed box are drugs with the same sensitivity differences predicted by both the TCGA and GEO cohortsBack to article page